pdufa.bio
HomeDecisionsAXSM 2026-04-30

AXSM FDA decision: Apr 30, 2026

Updated ·next FDA decision on the calendar
✓ APPROVED

Axsome Therapeutics Inc., AUVELITY (dextromethorphan HBr and bupropion · Agitation in patients with Alzheimer’s disease (AD.

Run-up into the decision (T-120 → T+5)

PDUFA 4/30/26$189.1$135.6911/13/25
Daily close, T-120 (11/13/25) through T+5. Run-up high $189.1 on 1/23/26, low $135.69 on 11/13/25 (T-120 to T-1). FDA decision 4/30/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-04-30
OutcomeApproved
Drug / candidateAUVELITY (dextromethorphan HBr and bupropion
CompanyAxsome Therapeutics Inc.
120-day run-up (T-120→T-1)+35.6%

Questions

Was AUVELITY (dextromethorphan HBr and bupropion approved by the FDA?

Yes. The FDA approved the application for AUVELITY (dextromethorphan HBr and bupropion on April 30, 2026. The primary source is linked on this page.

Which company is behind AUVELITY (dextromethorphan HBr and bupropion?

AUVELITY (dextromethorphan HBr and bupropion is a Axsome Therapeutics Inc. (AXSM) program. The FDA decision came on April 30, 2026; the company's own announcement is linked on this page.

How did AXSM stock trade into the FDA decision?

Measured over the 120 trading days before the decision (T-120 to T-1), AXSM moved +35.6%. That is the recorded price path into this specific event -- historical measurement, not a prediction, and not investment advice.